Derivatives of Rhodanine as Potential Antifungal Drugs by El Zein, Mariana
Charles University in Prague 
Faculty of Pharmacy in Hradec Králové 
Department of Pharmaceutical Chemistry and Drug Control 
 
 
 
 
 
 
 
 
 
Derivatives of Rhodanine as Potential Antifungal Drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hradec Králové, 2010 Marianna El-Zein 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is to declare that this diploma thesis is my own work and I worked on it on my own. 
All literature sources are properly cited in reference list. 
 
Date: Signature:  
 
The work was supported by the grant SVV-2010-261-001  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgement 
I would like to thank to Assoc. Prof. RNDr. V. Opletalová, Ph.D. for helping me in writing 
the thesis. I also thank to my parents for their support during my study. I would also like to 
thank to Ms. I. Vencovská for recording the IR spectra, and to Assoc. Prof. PharmDr.  
J. Kuneš, CSc. for recording and interpreting the NMR spectra.  
 
4 
 
CONTENT 
1. INTRODUCTION…………………………………..……… 7 
2. AIM OF THE WORK……………………………...…….. 9 
3. THEORETICAL PART…………………………………. 11 
3.1 Mycoses…………………………………………………… 11 
3.1.1 Advances and challenges in management of invasive mycoses 11 
3.1.1.1 Candida…………………………………………………………. 12 
3.1.1.2 Aspergillus………………………………………………………. 12 
3.1.1.3 Zygomycosis……………………………………………………… 12 
3.2 Drugs used for fungal infections…………………………… 13 
3.2.1. Classes of antifungal agents…………………………………… 13 
3.2.2 Polyenes…………………………………………………………. 14 
3.2.2.1. Mechanism of the action………………………………………….. 14 
3.2.2.2 Polyene Antifungals………………………………………………. 14 
3.2.2.3 Mechanisms of Resistance………………………………………… 16 
3.2.3. Azoles…………………………………………………………… 17 
3.2.3.1. Mechanism of action……………………………………………… 17 
3.2.3.2 Azole antifungals………………………………………………….. 17 
3.2.3.3 Spectrum of antifungal activity…………………………………….. 20 
3.2.3.4 Mechanism of resistance…………………………………………… 21 
3.2.4 Allyamines and Thiocarbamates………………………………. 21 
3.2.4.1 Mechanism of action……………………………………………… 21 
3.2.4.2 Antifungals……………………………………………………….. 21 
5 
 
3.2.4.3 Spectrum of antifungal activity…………………………………….. 23 
3.2.4.4 Mechanism of resistance…………………………………………… 23 
3.2.5 Echinocandins…………………………………………………… 24 
3.2.5.1 Mechanism of action………………………………………………. 24 
3.2.5.2 Echinocandin antifungals………………………………………….. 24 
3.2.5.3 Spectrum of antifungal activity…………………………………….. 26 
3.2.5.4 Mechanism of resistance…………………………………………… 26 
3.2.6 Griseofulvin……………………………………………………… 27 
3.2.7 Flucytosine………………………………………………………. 27 
3.2.8 Ciclopirox……………………………………………………….. 28 
3.2.9 Amorolfine………………………………………………………. 29 
4. EXPERIMENTAL PART………………………………… 30 
4.1 Preparation of (5Z)-5-arylmethylidene-2-thioxo-
1,3-thiazolidin-4-ones……………………………………………… 
 
31 
4.1.1 General Procedure……………………………………………… 31 
4.1.1.1 (5Z)-5-Benzylidene-2-thioxo-1,3-thiazolidin-4-one…………………... 31 
4.1.1.2 (5Z)-5-(4-Nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one…………... 31 
4.1.1.3 (5Z)-5-(4-Hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one……….. 32 
4.2 Preparation of (5Z)-5-benzylidene-3-[(diethylamino)-
methyl]-2-thioxo-1,3-thiazolidin-4-one I.……………………… 
 
33 
4.3 Preparation of (5Z)-5-benzylidene-3-[(diethylamino)- 
methyl]-2-thioxo-1,3-thiazolidin-4-one II.…………………….. 
 
34 
  
6 
 
4.4 Preparation of (5Z)-5-benzylidene-3-[(diethylamino)- 
methyl]-2-thioxo-1,3-thiazolidin-4-one III.…………………… 
 
36 
4.5 Preparation (5Z)-3-[(diethylamino)methyl]-5-(4-hydro-
xybenzylidene)-2-thioxo-1,3-thiazolidin-4-one………………. 
 
37 
4.6 Preparation (5Z)-3-[(diethylamino)methyl]-5-(4-nitro- 
benzylidene)-2-thioxo-1,3-thiazolidin-4-one…………………. 
 
38 
4.7 Preparation of (5Z)-5-benzylidene-3-(morpholin-4-yl- 
methyl)-2-thioxo-1,3-thiazolidin-4-one………………………… 
 
39 
5. DISCUSSION………………………………………………… 40 
6. CONCLUSIONS…………………………………………….. 43 
7. REFERENCES………………………………………………. 44 
 
7 
 
1. INTRODUCTION 
 Rhodanine (2-thioxo-1,3-thiazolidin-4-one) forms the basic skeleton of many 
biologically active substances and potential drugs [1]. Antifungal properties of 
rhodanine derivatives have been studied since the early 1950s [2]. The first attempts to 
use rhodanines as mildew-preventing agents were performed by Brown and co-workers. 
They studied various rhodanine derivatives with the aim to find new and effective 
compounds for protection of cotton fabrics against cellulolytic fungi and bacteria, e.g. 
Chaetomium globosum [3]. Condensation products of rhodanine and N-substituted 
rhodanines with various aldehydes were further studied by Allan et al. [4, 5]. Rhodanine 
derivatives were also tested against plant fungal pathogens – Alternaria tenuis and 
Botrytis allii [6]. 
5-(5-nitrofurfurylidene)rhodanine was the first rhodanine derivative tested 
against fungi that cause mycoses in mammals (Candida albicans and Trichophyton 
mentagrophytes) [7]. 
Since that time, plenty of various rhodanine derivatives have been studied as 
potential antifungal agents [1, 8–12]. Sortino and co-workers [13] tested a series of 
(Z5)-arylmethylidene rhodanines 2 against a panel of both standardized and clinical 
opportunistic pathogenic fungi. They have found that 
 the 2-thioxothiazolidin-4-one part itself, nor the presence of enone linkage is 
sufficient for antifungal activity 
 5-(subst.)benzylidenerhodanines were active, but 5-pyridylmethylidene-
rhodanines (all three positional isomers) were inactive 
 within the 5-(subst.)benzylidenerhodanines the type of substituents on the 
benzene ring plays an important role in activity 
 the most active compounds (F- and CF3-substituted benzylidenerhodanines) 
posses high log P values and low polarizability; replacement of fluorine with 
chlorine decreases potency, and substitution with bromine results in the loss of 
antifungal activity. 
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Independently of the research performed by Sortino et al. [13], antifungal effects of 
rhodanine derivatives were studied at the Charles University, Faculty of Pharmacy in 
Hradec Králové. In addition to (Z)-5-arylmethylidenerhodanines 1, (Z)-5-(1-
arylethylidene)rhodanines 2 derived from acetophenone, acetylpyridines and 
acetylpyrazine, and their analogs derived from 3-substituted rhodanines were prepared 
and tested against a panel of opportunistic pathogenic fungi (Candida albicans ATCC 
44859, Candida tropicalis 156, Candida krusei E 28, Candida glabrata 20/I, 
Trichosporon asahii 1188, Aspergillus fumigatus 231, Absidia corymbifera 272 and 
Trichophyton mentagrophytes 445. The results of these studies were more or less similar 
to those of Sortino et al. [14–20].  
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2. AIM OF THE WORK 
According to previous reports [3, 5, 6], 5-monosubstituted rhodanines are 
usually, but not always, more effective than their 3-alkyl or 3-phenyl analogs. In 1971, 
3-substituted rhodanines of general formula 3 were patented as potential antimicrobial 
compounds. The derivatives, where n = 0, R = H and R
1
 = methyl, ethyl, allyl, 
cyclopropyl, 2-OH-cyclohexyl, benzyl, 4-Cl-benzyl, inhibited growth of Candida 
albicans and Epidermophyton floccosum (MIC = ≤ 0.5 – 20 μg/ml). Unfortunately, 
MICs for other derivatives are not given in the patent [21, 22]. 
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A series of 5-substituted-3-polynitrophenylrhodanines inhibited the germination 
of spores of Helmithosporium sativum, Alternaria tenuis, Aspergilus niger and Fusarium 
oxysporum [8]. 
3-(2-Hydroxyethyl)rhodanines that have been studied at the Faculty of Pharmacy 
in Hradec Králové had better solubility in water, but lower antifungal potency than their 
3-unsubstituted congeners [23]. 
 Within the series of N-glycosylrhodanines the best activity against Candida 
albicans and Aspergilus niger was shown by N-(2,3,5-O-acetyl-β-D-
glucopyranosyl)rhodanine, which had comparable potency to that of rhodanine itself. 
The corresponding 5-benzylidene derivative was active against only C. albicans [24]. 
3-Aminorhodanines represent another type of 3-substituted derivatives. 
3-Amino-rhodanine (but not 3-acetylamino and 3-benzoylaminorhodanine) had better 
antifungal effectiveness than rhodanine [11]. Anilinorhodanines reported by Brown and 
co-workers [25] inhibited growth of Aspergilus niger. Within this series, 3-[(4-
halogenophenyl)-amino]-2-thioxo-1,3-thiazolidin-4-ones exhibited best potencies. 
Antifungal properties of  
condensation products of 3-aminorhodanine with aldehydes and ketones have not yet 
been studied in detail. (5Z)-3-Amino-5-(pyridin-2-ylmethylidene)-2-thioxo-
1,3-thiazolidin-4-on prepared by Hiršová [19] was ineffective.  
5-(Arylalkylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)alkanoic acids have also 
been reported as potential antifungal agents [12, 26]. Surprisingly, in a series of 
rhodanineacetic acids prepared at the Faculty of Pharmacy in Hradec Králové antifungal 
activity was only observed with {(5Z)-[4-oxo-5-(pyridin-2-ylmethylidene)-2-thioxo-
1,3-thiazolidin-3-yl]}acetic acid [27]. 
Antifungal properties have also been reported for Mannich bases derived from 
5-arylalkylidenerhodanines [28, 29]. This diploma project is a pilot study the aim of 
which is to study and optimize reaction conditions for Mannich reaction of 
(5Z)-5-(subst.)benzylidenes-2-thioxo-1,3-thiazolidin-4-ones with various amines. 
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3. THEORETICAL PART 
3.1 Mycoses 
During the past 20 years, the incidence of fungal infections in humans has risen in 
considerably. Fungal infections are categorized in two groups: topical and systemic 
fungal infections. 
 Topical fungal infections can be chronic and often resistant to treatment. 
Examples of these infections include athlete's foot, which is the most common 
fungal infection worldwide, and Candida infections of the mouth (oral 
candidiasis or thrush), which can result in periodontitis and gingival diseases. 
 Systemic fungal infections can occur in an organ or in the whole body and are 
transferred via the bloodstream. The two most important factors that are 
associated with the increase of fungal infections are the growth of 
immunocompromised patient population and the increased use of invasive 
devices (such as central venous catheters) and implants (prosthetic cardiac 
valves).  Systemic infections affect deeper tissues and organs. The commonest 
systemic fungal infections are blastomycosis, histoplasmosis, coccidiomycosis 
and paracoccidiomycosis [30–34].  
Fungi behave as opportunistic invaders and can cause life threatening infections in 
immunocompromised patients associated with modern high-intensity chemotherapy 
regimens [35], the acquired immunodeficiency syndrome (AIDS) pandemic, the more 
widespread use of solid organ transplantation [35], autologous and allogenic stem cell 
transplantation for haematologic malignancies [36, 37], and the use of aggressive 
supportive care in high-risk populations, especially those in intensive care units, burn 
patients [38] and premature neonates [39].  
 
3.1.1 Advances and challenges in management of invasive mycoses 
Invasive mycoses pose a major diagnostic and therapeutic challenge. Advances 
in antifungal agents and diagnostic methods offer the potential for improved outcomes in 
patients with these infections, which are often lethal. Many fungal pathogens occur 
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almost exclusively in opportunistic settings. Several areas of ongoing challenge remain, 
including the emergence of resistant organisms and the absence of reliable markers for 
early identification of patients at risk of developing invasive fungal disease 
 
3.1.1.1 Candida 
Candida is among the leading causes of nosocomial blood stream infections 
worldwide. Although risk factors for invasive candidosis are well known, including 
candida colonisation, length of hospital stay, abdominal surgery, and use of parenteral 
nutrition, antibiotics, or central vascular illness, few assesment strategies can predict 
a population at high risk of infection. Crude mortality rates for candidaemia have ranged 
from 30% to 61%, with significant attributable mortality related to Candida. The 
changing epidemiology of nosocomial candidaemia is due to several factors, including 
the widespread use of antifugals, particularly fluconazole. By contrast, Candida crusei is 
intrinsically resistant to fluconazole and itraconazole but usually susceptible to the 
newer triazoles and echinocandins. Candida glabrata, which has increased in many 
medical centres, shows dose-dependent susceptibility for many strains to fluconazole 
and itraconazole. 
 
3.1.1.2 Aspergillus 
Mortality rates associated with invasive aspergillosis are still extremely high, 
particularly in the most extensively immunosuppressed patients and those who develop 
disseminated infection. Species of Aspergillus other than Aspergillus fumigatus have 
been increasingly isolated, including Aspergillus terreus, a soil-related species that is 
often resistant to antifungal therapy, including amphotericin B. This species are 
generally more susceptible to echinocandins and newer azole antifungals, such as 
voriconazole and posaconazole, which appear to be better therapeutic options.  
 
3.1.1.3 Zygomycosis 
Zygomycosis (also known as mucormycosis) has recently received increased 
interest because of reports of these infections in severely immunosuppressed patients, 
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particularly those on long-term prophylaxis with voriconazole. Zygomycetes typically 
cause a syndrome of vascular invasion, thrombosis, and necrosis, which often presents 
as rhinocerebral infection but also as pulmonary or disseminated disease. The organisms 
causing this syndrome are in the order Mucorales, although Mucor spp. are uncommon 
causes of infection; genera include Rhizopus, Absidia, Cunninghamella, Apophysomyces 
elegans, and Saksenea vasiformis. The organisms form broad ribbonlike hyphae in 
tissued and are generally regarded as nonseptate, although rare septae may occur. These 
organisms may fail to grow from homogenized tissue, which can be a clue to their 
diagnosis. The organisms are identified by fruiting structures and presence and location 
of rhizoids-root like structures along the hyphae [40]. 
 
3.2 Drugs used for fungal infections 
3.2.1. Classes of antifungal agents 
Most antifungal drugs interfere with biosynthesis or integrity of ergosterol, the major 
sterol in the fungal cell membrane. Others cause disruption of the cell wall. Based on 
their mechanism of action the four main classes of antifungal drugs are the polyenes, 
azoles, allylamines and echinocandins. 
 Clinically useful "older" agents include topical azole formulations for superficial 
yeast and dermatophyte infections, first-generation triazoles (fluconazole and 
itraconazole) for a range of superficial and invasive fungal infections, 
amphotericin B formulations (for a broad range of invasive fungal infections and 
terbinafine for dermatophyte infections. 
 Clinically important "newer" agents include members of the echinocandin class 
(e.g., caspofungin, micafungin and anidulafungin) and second-generation 
triazoles (e.g., voriconazole and posaconazole, ravuconazole, albaconazole and 
isavuconazole).  
 Voriconazole and posaconazole have broad-spectrum activity against yeasts and 
moulds, including Aspergillus spp. Posaconazole is the only azole drug with 
activity against zygomycete fungi. 
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 Caspofungin and other echinocandins (micafungin and anidulafungin are 
effective in treating Candida and Aspergillus infections [41]. 
 
3.2.2 Polyenes 
Polyenes have a very broad range of activity against most pathogenic fungi. 
Polyene macrolides are a class of poorly absorbed, large macrocyclic polyketides that 
interact with membrane sterols. They are produced by Streptomyces spp, and 
characterized by large lactone rings, containing three to eight conjugated double bonds 
which are generally combined with one sugar moiety [42].  
 
3.2.2.1. Mechanism of the action 
The mode of action of polyenes is to increase the permeability of the cytoplasmic 
membrane, leading to leakage of the cell contents and eventually death. This action is 
dependent on binding of the antibiotic to sterols present in the cell membrane. 
Organisms, such as bacteria, which do not contain sterols, are inherently resistant to the 
polyenes. The different polyenes have differing affinities for sterols, and amphotericin 
has a higher affinity for ergosterol present in fungal cytoplasmic membranes than 
cholesterol, which is found in mammalian cell membranes [43]. 
 
3.2.2.2 Polyene Antifungals 
Amphotericin B (AmB) is the most widely used member of this group. It has 
been for many years the only antifungal polyene that could be administered 
systematically to treat a visceral infection. AmB is useful in treating cases of candidosis, 
cryptococcosis. This natural compound was isolated from Streptomyces nodosus in 1955 
[44]. Amphotericin B is still considered the gold standard for the treatment of most life-
threatening fungal infections [42]. Locally it is used only for therapy of candidoses; 
intravenously it is used for therapy of infections cause by Cryptococcus neoformans, by 
Aspergillus but mainly infections caused by Candida. Amphotericin B has to be 
administered intravenously because peroral administation is not effective. There is a 
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danger of neophrotoxicity that’s why the dosage of amphotericin B should be proper 
[44].  
AmBisome is a medicinal product in which AmB is integrated into unilamellar 
liposomes. The ingredients are supplied lyophilized as a powder and must be 
reconstituted in water directly before use, producing liposomes with a mean diameter of 
60-70 nm. The liposomal material consists if hyfrogenated soy bean lecitine, 
phosphocholine, cholesterol, and sucrose for an isotonic milieu, with α-tocopherol and 
disodium succinate hydrate. When AmB containing liposomes come into contact with 
fungal cells or Leishmania organisms, the liposomal matrix is degraded and AmB is set 
free to bind preferentially to ergosterol in the cell membrane, leading its disintegration 
[45]. 
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Nystatin is obtained from Streptomyces noursei and is used only locally against 
candidosis. It can be administered even in form of aerosol [44]. 
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Natamycin is obtained from Streptomyces natalensis and it is used for local 
therapy as same as nystatin [44]. 
 
natamycin 
 
3.2.2.3 Mechanisms of Resistance 
Resistance to AmB is quite rare and is often caused by a decrease in the amount 
of ergosterol in the plasma membrane leading to a decrease in the binding of AmB. 
Moreover, some fungal cells have a mutation in their ergosterol biosynthesis pathway 
such that instead of producing ergosterol they can produce ergosterol-like compounds, 
for which AmB has lower binding affinity [42].  
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3.2.3. Azoles 
Until the 1940s, relatively few agents were available for the treatment of 
systemic fungal infections. The development of the polyene antifungals represented a 
major advance in medical mycology. Although amphotericin B quickly became the 
mainstay of therapy for serious infections, its use was associated with infusion-related 
side-effects and dose-limiting nephrotoxicity. The continued search for new and less 
toxic antifungals led to the discovery of the azoles several decades later. Azole 
antifungals are divided into the imidazoles (e.g. miconazole and ketoconazole) and the 
triazoles (e.g. itraconazole, fluconazole, voriconazole) [46]. 
 
3.2.3.1. Mechanism of action 
The azoles inhibit the fungal cytochrome P450 3A (CYP3A) enzyme, lanosterol 
14α-demethylase which is responsible for converting lanosterol to ergosterol, the main 
sterol in fungal cell membrane. The resulting depletion of ergosterol alters the fluidity of 
the membrane and this interferes with the action of membrane-associated enzymes. The 
net effect is an inhibition of replication. Azoles also inhibit the transformation of 
candidal yeast cells into hyphae – the invasive and pathogenic form of the parasite. The 
depletion of membrane ergosterol reduces the binding sites for amphotericin [47]. 
 
3.2.3.2 Azole antifungals 
Azole antifungals have two active groups which contain imidazole or triazole 
cycle. Imidazole derivatives are mainy used locally. They are used for treatment of 
infections caused by dermatophytes as Trichophyton, Microsporon and Epidermophyton; 
they are applicable also to candidosis and infections caused by Cryptococcus spp. 
Imidazole derivatives are administered in the form of creams or solutions. Treatment by 
itself takes weeks or even months. Miconazole is mostly given intravenously or orally 
for infections of the gastrointestinal tract or also topically [47]. It is not used so much 
because of tolerance in the body. There are more side effects (dizziness, iritations, even 
fever) than positive effects [44]. Clotrimazole, econazole, tioconazole and sulconazole 
are azole antifungal agents used only for topical application. Clotrimazole interferes 
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with amino acid transport into the fungus by an action on the cell membrane. It is active 
against a wide range of fungi, including candidal organisms [47]. 
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Fluconazole has good overall activity against Candida spp. and Cryptococcus 
neoformans. However, resistance to the drug is encountered in certain non-albicans 
Candida spp. such as C. crusei and some isolates of C. glabrata. It is available as oral 
and intravenous formulations. Fluconazole is commonly given once daily, but can be 
prescribed twice daily for larger total daily doses.  
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Itraconazole has activity against yeasts and some moulds (including 
Aspergillus), but is disadvantaged by variable bioavailability and an unpleasant taste. 
Two oral formulations are available: capsule and oral solution. The bioavailability of the 
capsule form is highly influenced by concomitant food intake, and there is considerable 
intra- and inter- patient variability in plasma drug concentrations; the solution form has a 
more favourable pharmacokinetic profile. Itraconazole is usually given twice daily [41]. 
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Voriconazole and posaconazole have an extended spectrum of activity against 
yeasts, e.g. C. neoformans, and moulds, including Aspergillus, Scedosporium, and 
Fusarium spp. Voriconazole is active against fluconazole-resistant Candida spp. [41]. 
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Ravuconazole is under investigation for the treatment of systemic fungal 
infections [48]. 
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3.2.3.3 Spectrum of antifungal activity 
Azole antifungals have a broad spectrum of antifungal activity. They are active 
against Candida spp., C. neoformans and dimorphic fungi. Some azole antifungals are, 
however, more active than others in different cases. For example, fluconazole is 
relatively inactive against C. krusei as opposed to itraconazole. Azole antifungals are 
only fungistatic against most yeast species with the exception of C. neoformans. Mature 
Candida biofilms exhibit profound resistance to azoles [49]. 
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3.2.3.4 Mechanism of resistance 
Different mechanisms have been implicated in the development of MDR, 
including over expression of genes encoding drug efflux pumps, alteration of membrane 
sterol composition and overproduction or mutation in the target enzyme of the azoles, 
lanosterol-14α-demethylase [49]. 
 
3.2.4 Allyamines and Thiocarbamates 
Two classes of synthetic antimycotics, namely allylamines (notably terbinafine 
and naftifine) and the structurally related thiocarbamates (such as tolnaftate) are mainly 
used for the treatment of topical infections caused by dermatophytes. The prototype of 
the allylamines, naftifine, proved to be an efficacious antimycotic for topical aplications 
in dermatophytes and was the starting point for studies on structure-activity 
relationships, resulting in the development of terbinafine, an allylamine with 
considerably enhanced antifungal properties [42]. 
 
3.2.4.1 Mechanism of action 
Compounds of this class act by selectively inhibiting the enzyme squalene 
epoxidase which is involved in the synthesis of ergosterol from squalene in the fungal 
cell wall. The accumulation of squalene within the cell is toxic to the organism [47]. 
 
3.2.4.2 Antifungals 
Naftifine is a topical allylamine that is effective and safe in the management of 
superficial dermatomycoses. It is moderately active in vitro against moulds, but is 
generally less active against yeasts, including Candida albicans. However, it has proved 
reasonably effective in the treatment of patients with cutaneous candidiasis [50].   
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Terbinafine is the first orally active compound in the allylamine family. It has 
fungicidal activity against dermatophytes, moulds and certain dimorphic fungi, and 
fungistatic activity against Candida albicans. Following oral administration the 
terbinafine is absorbed rapidly [51, 52]. 
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Tolnaftate is a thiocarbamate that is active only against growing dermatophytes. 
The mode of action is the inhibition of squalene epoxidase.  It is used topically in the 
treatment or prophylaxis of superficial dermatophyte infections and of pityriasis 
versicolor [52]. 
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Another thiocarbamate derivative is tolciclate which is used for skin mycoses 
(tinea corporis, tinea cruris, tinea pedis, tinea manuum and pityriasis versicolors 
versicolor) [53, 54].  Also liranaftate is an efficacious agent for the treatment of 
dermatophytes. It has been developed in Japan [55]. 
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3.2.4.3 Spectrum of antifungal activity 
Terbinafine is mainly active on dermatophytes, including Trichophyton rubrum, 
T. verrucosum, Microsporum canis and Epidermophyton floccosum. Terbinafine also has 
in vitro activity against most Candida spp., Aspergillus spp., Penicillium marneffei, 
Malassezia furfur, Cryptococcus neoformans, Trichosporon spp. and Blastoschizomyces 
spp. The use of tolnaftate is essentially restricted to dermatophyte infections such as 
M. canis and T. mentagrophytes [30]. 
 
 
3.2.4.4 Mechanism of resistance 
Resistance to allylamines has been reported only rarely. However, the potential 
to develop resistance by the action of multidrug efflux transporters does exist. 
Resistance to thiocarbamates has not been extensively studied. A study on the mode of 
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action of tolnaftate in M. gypseum revealed a higher content of total phospholipids in 
tolnaftate-resistant cells compared to wild type cells [42]. 
 
3.2.5 Echinocandins 
Echinocandins were discovered in 1970s and are inhibitors of the cell wall 
formation. They are derivatives of fatty acids and cyclic hexapeptides. The various 
echinocandins differ in having different substituents in the hexapeptide ring or a distinct 
fatty acid chain [56–59]. 
 
3.2.5.1 Mechanism of action 
Echinocandins are secondary metabolites comprising a cyclic hexapeptide core 
with a lipid side chain responsible for antifungal activity. The target for echinocandins is 
the complex of proteins responsible for synthesis of cell wall β-1,3-glucan 
polysaccharides. The target of echinocandins does not exist in mammalian cells, so their 
toxicity is minimal. The first of the class to be licensed was caspofungin for refractory 
invasive aspergillosis and the second was micafungin.  [56–59]. 
 
3.2.5.2 Echinocandin antifungals 
Caspofungin was approved by the FDA in 2001. It is highly active in vitro 
against most isolates of Candida spp. It also has in vitro inhibitory activity against 
Aspergillus spp nad moderaze activity against some other moulds. It is also active 
against Pneumocystis carinii. In contrast, it has no activity against Cryptococcus 
neoformans, Trichosporon spp., Sporothrix schenckii, zygomycetes and 
hyalohyphomycetes. Caspofungin appears to be a suitable antifungal agent in patients 
with oesophageal candidiasis refractory to fluconazole [58]. 
 
Micafungin became available in 2005. It was approved for the treatment of 
oesophageal candidiasis as well as prophylaxis in patients undergoing stem cell 
transplantation [58]. 
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Anidulafungin was approved in 2006 for use in the treatment of oesophageal 
candidiasis, candidaemia, peritonitis and untra-abdominal abscesses due to Candida spp. 
It slowly degrades in humans, it has a half-live of approximately 25 hours [58]. 
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3.2.5.3 Spectrum of antifungal activity 
In vitro and in vivo, echinocandins are rapidly fungicidal against most Candida 
spp. and fungistatic against Aspergillus spp. Echinocandins are not active at clinically 
relevant concentrations against C. neoformans or Fusarium spp. Echinocandins show 
activity against Candida biofilms, which exhibit resistance to other antifungal agents 
such as azoles [42].  
 
3.2.5.4 Mechanism of resistance 
The resistance to echinocandins is very rare [42]. However, as patient exposure 
to echinocandin drugs broadens, the number of infecting strains with reduced 
susceptibility is expected to rise. Although a prospective global surveillance study 
(2001–2006) did not observe echinocandin resistance in invasive candidiasis isolates, 
cases of breakthrough mycoses during echinocandin use or of echinocandin-resistant 
isolates are being increasingly reported [60, 61]. Unfortunately, the relationship between 
reduced in vitro susceptibility to echinocandin drugs and clinical failure is ambiguous 
The (1,3)-β-glucan synthase is a multi-subunit enzyme complex responsible for fungal 
cell wall construction and division septum deposition. The enzyme catalyses the transfer 
of sugar moieties from activated donor molecules to specific acceptor molecules forming 
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glycosidic bonds in the reaction UDP-glucose + {(1,3)-β-D-glucosyl}(N) → UDP + 
{(1,3)-β-D-glucosyl}(N+1). . The UDP glycosyltransferases are one group of enzymes 
that carry out this reaction and over 100 members of this protein family are known. The 
enzyme complex has a minimum of two subunits, Fks1 and Rho. Fks1 appears to be the 
catalytic subunit. Recent work has shown that spontaneous mutations can arise in two 
hot spot regions of Fks1 that reduce the enzyme’s sensitivity to the drug. However, other 
strains have been isolated in which the sequence of Fks1 is unaltered yet the fungus has 
decreased sensitivity to echinocandins. In addition it has been shown that echinocandin-
treatment can induce cell wall salvage mechanisms that result in the compensatory 
upregulation of chitin synthesis in the cell wall. This salvage mechanism strengthens cell 
walls damaged by exposure to echinocandins. Therefore, fungal resistance to 
echinocandins can arise due to the selection of either stable mutational or reversible 
physiological alterations that decrease susceptibility to these antifungal agents [62]. 
 
3.2.6 Griseofulvin 
The earliest inhibitory agent specific to fungal species was griseofulvin. The 
precise mechanism of action of this compound is still unknown, but the favoured 
explanation is that it interferes with microtubule assembly. Its spectrum of action is 
restricted mainly to the dermatophyte, i. e. fungi causing ringworm and athlete’s foot 
[56, 63]. 
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3.2.7 Flucytosine 
Flucytosine works as an antifungal agent through conversion to 5-fluorouracil 
within the target cells. Fluorouracil becomes incorporated into RNA, causing premature 
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chain termination, and it inhibits DNA synthesis through effects on thymidylate 
synthase. The useful spectrum of flucytosine is restricted to pathogenic yeasts such as 
Candida spp. and C. neoformans. Flucytosine is used as adjunctive, rather than primary 
therapy, in the clinic, because primary and secondary resistance may occur at a high 
frequency [56]. 
N
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3.2.8 Ciclopirox 
Ciclopirox is a member of the hydroxypyridine family. It is believed to work by 
inhibiting metal-dependent enzymes by chelating the polyvalent cations (Fe
3+
 or Al
3+
). 
This affects intracellular energy production and toxic peroxide degradation. It also 
inhibits fungal nutrient uptake, resulting in decreased nucleotides and a reduction in 
protein synthesis [64, 65]. Ciclopirox has a wide spectrum of antifungal activity. It 
inhibits most Candida, Epidermophyton, Microsporum, and Trichophyton spp. and is 
also active against Malassezia furfur. It is applied topically in the treatment of fungal 
skin and nail infections. It has also been used in the treatment of vaginal candidiasis. It is 
applied twice daily for skin infections, as a cream, gel, suspension, solution, or powder; 
both the base and the olamine salt have been used. A lacquer containing 8% ciclopirox 
base is applied once daily for nail infections.  A shampoo containing 1% ciclopirox base 
is used twice weekly for the treatment of seborrhoeic dermatitis [66]. 
N
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O
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3.2.9 Amorolfine 
Amorolfine is another type of local antimycotics. It is a morfoline derivate, 
which inhibits synthesis of sterols in fungi. Amorolfine has wide spectrum of action 
against dermatophytes, various filamentous and dematiaceous fungi, yeasts and 
dimorphic fungi. Its activity is fungicidal for most species [64].  It is applied topically as 
the hydrochloride in the treatment of fungal nail and skin infections For the treatment of 
nail infections caused by dermatophytes, yeasts, and moulds a lacquer containing the 
equivalent of 5% amorolfine is painted onto the affected nail once or sometimes twice 
weekly until the nail has regenerated. Treatment generally needs to be continued for 6 to 
12 months. For skin infections a cream containing the equivalent of 0.25% amorolfine is 
applied once daily for at least 2 to 3 weeks (up to 6 weeks for foot infections) and 
continued for 3 to 5 days after clinical cure is achieved [66]. 
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4. EXPERIMENTAL PART 
Commercially available substances were used for the preparation of 
(5Z)-5-arylmethylidene-2-thioxo-1,3-thiazolidin-4-ones  
 benzaldehyde, rein (FERAK Laborat, Berlin, Germany) 
 4-nitrobenzaldehyde (Lachema, Neratovice, Czech Republic) 
 4-hydroxybenzaldehyde zur Synthese (Merck, Darmstadt, Germany) 
 rhodanine, puriss. p. a. (Fluka, International) 
 
For the preparation of Mannich bases, formaldehyde solution, 37% (Sigma, 
International), diethylamine, purum (Fluka, International) and morpholine, p. a. 
(International Enzymes, Windsor, Berks., UK) were used. 
 
TLC was performed on TLC aluminium sheets, Silica gel 60 F254 (Merck, Darmstadt, 
Germany). Light petroleum + ethyl acetate 80:20 (v/v) and 60:40 were used as a mobile 
phases. 
 
For analysis, the samples of compounds were dried 24 hours in a dessicator at 1.33 kPa. 
  
Melting points were determined using Boëtius apparatus HMK (VEB Analytik, Dresden, 
Germany) and are uncorrected. 
 
IR spectra were recorded using the spectrophotometer NICOLET 6700. Wavenumbers 
are given in cm
-1
. 
 
1
H-NMR and 
13
C-NMR spectra were recorded with the VARIAN Mercury-VxBB 300. 
Chemical shifts are given in δ, ppm and interaction constants J in Hz. 
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4.1 Preparation of (5Z)-5-arylmethylidene-2-thioxo-1,3-
thiazolidin-4-ones 
 
4.1.1 General Procedure 
An equimolar amount of the aldehyde and rhodanine (0.015 mol) was heated under 
reflux condenser with ethanol (15 ml) and concentrated ammonia solution (1.1 ml) until 
all solid components dissolved. Solution of ammonium chloride (1.00 g) in 2 ml of hot 
(80 °C) distilled water was then added, and the reaction mixture was refluxed for 2 
hours. After cooling, the separated solid was filtered through a sintered glass, washed 
with distilled water (50 ml) and then with 50% ethanol (50 ml). The product was 
crystallized from anhydrous ethanol. 
 
4.1.1.1 (5Z)-5-Benzylidene-2-thioxo-1,3-thiazolidin-4-one 
 
H
NH
S
O
S  
Yield: 86% 
Yellow crystalline compound 
M. p. 205 – 207 °C (206 – 207 °C [15]) 
 
4.1.1.2 (5Z)-5-(4-Nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one 
 
H
NH
S
O
S
N
+
O
-
O  
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Yield: 82% 
Orange crystalline compound 
M. p. 273 – 274 °C (272 – 276 °C [16]) 
 
4.1.1.3 (5Z)-5-(4-Hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one 
 
H
NH
S
O
S
OH
 
Yield: 84% 
Orange crystalline compound 
M. p. 285 – 290 °C (294 – 295 °C [15]) 
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4.2 Preparation of (5Z)-5-benzylidene-3-[(diethylamino)- 
methyl]-2-thioxo-1,3-thiazolidin-4-one I.  
 
H
NH
S
O
S
formaldehyde
diethylamine
ethanol

H
N
S
O
S
N
CH3
CH3
 
 
(5Z)-5-Benzylidene-2-thioxo-1,3-thiazolidin-4-one (2.21 g, 0.01 mol) was suspended in 
hot ethanol (30 ml) and formaldehyde solution (37%, 2 ml) was added, followed by 
diethylamine (0.73 g, 0.01 mol). The reaction mixture was heated on a glycerin bath for 
15 minutes under stirring and left overnight at room temperature. Since no solid 
separated under these conditions, the solution was refrigerated for several days. Only a 
very small amount of a yellow compound precipitated. Approximately half of ethanol 
was evaporated under reduced pressure. After cooling, 0.94 g of yellow powder was 
obtained. Crystallization from the anhydrous ethanol then yielded 0.43 g of yellow, 
finely crystalline substance. The substance was identified to be starting (5Z)-5-
benzylidene-2-thioxo-1,3-thiazolidin-4-one. 
Rf = 0.43 (light petroleum + ethyl acetate 80:20) 
M. p. = 205 – 210 °C (206 – 207 °C [15]) 
 
Chromatography of combined mother liquors yielded 0.73 g of yellow substance, Rf of 
which corresponded to starting (5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one, and 
several smaller fractions. Based on NMR results, none of these fractions contained 
(Z)-5-benzylidene-3-[(dimethylamino)methyl]-2-thioxothiazolidin-4 one. 
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4.3 Preparation of (5Z)-5-benzylidene-3-[(diethylamino)- 
methyl]-2-thioxo-1,3-thiazolidin-4-one II. 
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(5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one (2.21 g, 0.01 mol) was suspended in 
hot ethanol (30 ml) and formaldehyde solution (37%, 2 ml) was added, followed by 
diethylamine (0.73 g, 0.01 mol). The reaction mixture was heated on a glycerin bath for 
10 hours under stirring and left overnight at room temperature. Since no solid separated 
under these conditions, the solution was refrigerated for several days. A small amount of 
a solid precipitated. The solid was filtered off, washed with a small amount of cold 
ethanol and dried. According to NMR, it was not the required Mannich base.  
 
Mother liquors contained a mixture of compounds that were separated using column 
chromatography. 
Chromatographic conditions: 
Silica gel 60, 0.043 – 0.060 mm, Merck – 100 g 
Volume of a fraction – 25 ml 
TLC for all fractions performed in light petroleum + ethyl acetate 80:20 
 
Fractions Mobile phase Rf 
Weight 
(g) 
Characterization 
1 – 7 
light petroleum +  
ethyl acetate 80:20 
----- ----- returned to the column 
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8 – 11 
light petroleum +  
ethyl acetate 80:20 
0.73 0.11 
reddish-brown oil; it does not 
contain the required Mannich 
(based on NMR results) 
12 – 13 
light petroleum +  
ethyl acetate 80:20 
0.48 0.02 
yellow oil, it does not contain 
the required Mannich  
(based on NMR results) 
14 – 25 
light petroleum +  
ethyl acetate 80:20 
0.63 
0.43 
0.25 
1.66 
Yellow powder; a mixture of 
compounds in which starting 
(5Z)-5-benzylidene-2-thioxo-
1,3-thiazolidin-4-one prevails; 
26 – 37 
light petroleum +  
ethyl acetate 60:40 
37 – 56 
light petroleum +  
ethyl acetate 60:40 
0.43 
0.10 
0.18 
yellow oil; it does not contain 
the required Mannich (based 
on NMR results) 
57 – 100 methanol 0.00 0.10 semisolid substance 
 
Crystallization of combined fractions 14 – 37 
The crude yellow substance was crystallized from the anhydrous ethanol. The 
crystallization yielded 0.48 g of yellow, finely crystalline substance that was identified 
to be starting (5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one. 
Rf = 0.43 (light petroleum + ethyl acetate 80:20) 
M. p. = 205 – 207 °C (206 – 207 °C [15]). 
 
Crystallization of combined fractions 57 – 100 
The semisolid substance was refluxed with 75 ml of anhydrous ethanol, but it did not 
dissolved completely. After cooling, the solid was filtered off and dried. 0.06 g of an off-
white substance melting at 155 – 165 °C. 
Unfortunately, NMR of the compound did not correspond to the structure of the required 
Mannich base. 
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4.4 Preparation of (5Z)-5-benzylidene-3-[(diethylamino)- 
methyl]-2-thioxo-1,3-thiazolidin-4-one III. 
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(5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one (2.21 g, 0.01 mol) was suspended in 
dimethylformamide (30 ml) and diethylamine (0.73 g, 0.01 mol) was added, followed by 
formaldehyde solution (37%, 1.1 ml). The resulting mixture was stirred for 11 hours at 
room temperature. Then it was poured into cold water (50 ml) and refrigerated 
overnight. The separated solid was filtered off and dried. A yellow substance (0.19 g) 
was obtained. According to TLC, it was a mixture of the starting (5Z)-5-benzylidene-2-
thioxo-1,3-thiazolidin-4-one (major zone) and another substance (minor zone). 
Crystallization from anhydrous ethanol gave 0.06 g of a yellow powder that was 
identified to be starting (5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one. 
Rf = 0.43 (light petroleum + ethyl acetate 80:20) 
M.p = 205 – 209 °C (206 – 207 °C [15]). 
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4.5 Preparation (5Z)-3-[(diethylamino)methyl]-5-(4-hydroxy- 
benzylidene)-2-thioxo-1,3-thiazolidin-4-one 
 
H
NH
S
O
S
OH
formaldehyde
diethylamine
DMF
H
N
S
O
S
N
CH3
CH3
OH
 
 
(5Z)-5-(4-Hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one (1.19 g, 5 mmol) was 
suspended in dimethylformamide (15 ml) and diethylamine (0.37 g, 5 mmol) was then 
added, followed by formaldehyde solution (37%, 0.55 ml ). The resulting mixture was 
stirred for 11 hours at room temperature. Then it was poured into cold water (25 ml) and 
refrigerated overnight. The separated solid was filtered off and subjected to column 
chromatography using silica gel 60, 0.043 – 0.060 mm (Merck) as the adsorbent and 
light petroleum + ethyl acetate 60:40 as the eluent. Volume of a fraction was 20 ml. 
Crystalization of fractions 17 – 23 gave 0.23 g of an orange compound that was 
identified to be starting (5Z)-5-(4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one. 
Rf = 0.40 (light petroleum + ethyl acetate 60:40)  
M.p = 288 – 295 °C (294 – 295 °C [15]). 
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4.6 Preparation (5Z)-3-[(diethylamino)methyl]-5-(4-nitro- 
benzylidene)-2-thioxo-1,3-thiazolidin-4-one 
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(5Z)-5-(4-Nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one (3.51 g, 0.01 mol) was 
suspended in dimethylformamide (30 ml) and diethylamine (0.73 g, 0.01 mol) was 
added, followed by formaldehyde solution (37%, 1.1 ml). The resulting mixture was 
stirred for 11 hours at room temperature. Then it was poured into cold water (50 ml) and 
refrigerated overnight. Orange-brown substance (3.43 g) was obtained after filtration 
and drying. According to TLC, it was a mixture of the starting 
(5Z)-5-(4-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one (major zone) and some other 
compounds. Crystallization from anhydrous ethanol did not yield an identifiable 
compound. 
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4.7 Preparation of (5Z)-5-benzylidene-3-(morpholin-4-yl- 
methyl)-2-thioxo-1,3-thiazolidin-4-one 
 
H
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DMF
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N
O
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(5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one (2.21 g, 0.01 mol) was suspended in 
dimethylformamide (30 ml) and morpholine (0.87 g, 0.01 mol) was added, followed by 
formaldehyde solution (37%, 1.1 ml). The mixture was stirred for 11 hours at room 
temperature.  Then it was poured into cold water (50 ml) and refrigerated overnight. The 
separated solid was filtered off and dried. Yellow crystals (4.54 g) were obtained. 
Crystallization from anhydrous ethanol gave 2.88 g (90%) of yellow powder that was 
identified as the required Mannich base. 
 
Molecular weight: 320.43 (C15H16N2O2S2) 
Melting point: 120 – 125 °C 
IR spectrum (ATC, cm
-1
): 2949, 2850 (CH) 1704 (C=O) 
1
H NMR (300 MHz, DMSO)  7.75 (1H, s, CH), 7.66 – 7.59 (2H, m, H2´, H6´), 7.59 – 
7.48 (3H, m, H3´, H4´, H5´), 4.90 (2H, s, NCH2), 3.51 (4H, t, J = 4.6, OCH2), 2.64 (4H, 
t, J = 4.6 Hz, NCH2) 
13
C NMR (75 MHz, DMSO)  196.1, 168.9, 133.3, 132.6, 131.0, 130.8, 130.8, 129.7, 
66.2, 65.4, 51.5 
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5. DISCUSSION 
The first Mannich reaction was made in 1912 by Carl Mannich by reaction of 
salicylantipyrine and hexamethylenetetramine Mannich published more than 60 papers 
on this topic, one fifth of his wide scientific production, which ended with his death, in 
1947. Since then, Mannich bases have been subjects of growing interest [67]. 
The Mannich reaction is a three-component condensation in which a compound 
containing an active hydrogen atom (substrate) is allowed to react with formaldehyde 
and an NH-amine derivative  
 
R H + CH2O + R N
R
2
R
1
NH
R
2
R
1
-H2O
 
 
The resulting product (the Mannich base) is an amine compound having the 
N-atom linked to the R-substrate through methylene group. The substrate may belong to 
a number of different classes of compounds [67]. 
Unsubstituted rhodanine can react with formaldehyde in either position 3 or 
position 5 or both forming theoretically three types of Manich bases 
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Mannich bases of type A were reported by Indian researchers [68], whilst 
Mannich bases of type B and C have not been reported so far.  
Mannich bases of 3-substituted rhodanines of general formula 1 were studied by 
Das et al. [69]. 
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The most common type of 5-substituted rhodanines are (5Z)-5-arylalkylidene-
2-thioxo-1,3-thiazolidin-4-ones that form Mannich bases of general formula 2 [28, 29, 
70–78]. 
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The aim of my diploma thesis was to find suitable reaction conditions for 
Mannich reaction of (5Z)-5-(subst.)benzylidenes-2-thioxo-1,3-thiazolidin-4-ones with 
various amines. To manage to produce some Mannich reaction I have worked with 
benzylidenerhodanines which were reacting with the compounds necessary for making 
Mannich base. 
I have first attempted to prepare (5Z)-5-benzylidene-3-[(diethylamino)-methyl]-
2-thioxo-1,3-thiazolidin-4-one using the method reported by Sen Gupta et al. [28] who 
used ethanol as the reaction solvent, but only unreacted (5Z)-5-benzylidene-2-thioxo-
1,3-thiazolidin-4-one was obtained (part. 4.2). 
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 The second experiment (part 4.3) was made after the same authors but the 
reaction mixture was heated on a glycerin bath for 10 hours. However, this modification 
did not resulted in the required product either.  
The 3
rd
 experiment according to Gaikwad and Gautam [77] where 
(5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one was suspended in 
dimethylformamide (part 4.4) was unsuccessful, and only unreacted (5Z)-5-benzylidene-
2-thioxo-1,3-thiazolidin-4-one was obtained.  
Similar results were then achieved in the experiment 4.5 with 
(5Z)-5-(4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one. 
The reaction mixture from the experiment 4.6. was not chromatographically 
separated due to the lack of time. Nonetheless, it can be expected that only starting 
(5Z)-5-(4-nitrobenzylidene)-2-thioxo-1,3-thiazolidin-4-one would be obtained. 
These results are rather surprising since (5Z)-5-benzylidene-3-[(diethylamino)-
methyl]-2-thioxo-1,3-thiazolidin-4-one was previously described by Das et al. [68] and 
by Gaikwad and Gautam [77]. (5Z)-3-[(Diethylamino)methyl]-5-(4-nitrobenzylidene)-2-
thioxo-1,3-thiazolidin-4-one was prepared by Shukla and co-workers [72]. Only 
(5Z)-3-[(diethylamino)methyl]-5-(4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one 
has not been reported in literature so far. 
In the last experiment, (5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one was 
treated with morpholine and formaldehyde, and the required (5Z)-5-benzylidene-3-
(morpholin-4-yl-methyl)-2-thioxo-1,3-thiazolidin-4-one was successfully obtained. Its 
identity was corroborated with IR and NMR results. The product was also submitted to 
elemental analysis to determine its purity, but the results have not yet been at my 
disposal. This compound was reported previously [29, 68] and exhibited antibacterial 
activity and acceptable toxicity [79]. Hence, Mannich bases derived from (5Z)-5-
arylalkylidene-2-thioxo-1,3-thiazolidin-4-ones deserve further attention as potential 
antimicrobial agents. 
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6. CONCLUSIONS 
  
The aim of my diploma thesis was to find suitable reaction conditions for 
Mannich reaction of (5Z)-5-(subst.)benzylidenes-2-thioxo-1,3-thiazolidin-4-ones with 
various amines. 
 
The attempts to prepare Mannich bases using diethylamine as the basic 
component were unsuccessful. 
 
(5Z)-5-benzylidene-3-(morpholin-4-yl-methyl)-2-thioxo-1,3-thiazolidin-4-one 
was obtained by treating (5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one with 
formaldehyde and morpholine in dimethylformamide. 
 
Based on the data obtained from literature, Mannich bases derived from (5Z)-5-
arylalkylidene-2-thioxo-1,3-thiazolidin-4-ones deserve further attention as potential 
antimicrobial agents. 
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Rhodanine (2-thioxo-1,3-thiazolidin-4-one) forms the basic skeleton of many 
biologically active substances and potential drugs. Antifungal properties of rhodanine 
derivatives have been studied since the early 1950s. 
Theoretical part of the thesis deals with mycoses and drugs that are currently 
used to treat them. The aim of the experimental work was to find suitable reaction 
conditions for Mannich reaction of (5Z)-5-(subst.)benzylidenes-2-thioxo-1,3-thiazolidin-
4-ones with various amines. The attempts to prepare Mannich bases using diethylamine 
as the basic component were unsuccessful. (5Z)-5-benzylidene-3-(morpholin-4-yl-
methyl)-2-thioxo-1,3-thiazolidin-4-one was successfully obtained by treating 
(5Z)-5-benzylidene-2-thioxo-1,3-thiazolidin-4-one with formaldehyde and morpholine 
in dimethylformamide. This compound was reported previously and exhibited 
antibacterial activity and acceptable toxicity. Hence, Mannich bases derived from 
(5Z)-5-arylalkylidene-2-thioxo-1,3-thiazolidin-4-ones deserve further attention as 
potential antimicrobial agents. 
 
 
 
 
 
